Mark McKenna

The pace of innovation in biotech: Mirador’s Mark McKenna

Mark McKenna, Dan Dees

Former Prometheus Biosciences CEO Mark McKenna discusses the transformation of the biotech landscape from a pharma-dominated field to one driven by agile, high-risk companies like his current venture, Mirador Therapeutics, which recently secured $400 million in rapid fundraising. Drawing on his experience leading the $11 billion Merck acquisition of Prometheus, McKenna emphasizes that success now relies on leveraging generative AI for precision medicine, operating with a "speed as currency" philosophy to parallelize trials, and maintaining strategic secrecy to protect intellectual property against global competitors. The dialogue further outlines critical industry challenges, including the need to reform drug pricing models dominated by PBMs and to de-risk supply chains from over-reliance on Chinese manufacturing.